Cost-effectiveness of anti tuberculosis medicines (Bedaquiline, Delamanid, Linezolid and combination) based on Quality-Adjusted Life-Years (QALYs) versus Disability-Adjusted Life-Years (DALYs)
Not Applicable
- Conditions
- Health Condition 1: Z870- Personal history of diseases of the respiratory system
- Registration Number
- CTRI/2024/08/071882
- Lead Sponsor
- Shah Paras Jagdishkumar
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Data of adult (=18 years of age) MDR or XDR-TB patients of either gender on Bedaquiline/Delamanid/Linezolid/Combinations.
Exclusion Criteria
1) Data containing inadequate details
2) Anti-Retroviral Therapy in addition to data meeting inclusion criteria
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1) Cost-effectiveness of bedaquiline (Bdq), delamanid (Dlm), linezolid (Lzd) and their combinations based on QALYs versus DALYs <br/ ><br>2) Other pharmacoeconomic variables like cost-utility, cost-benefit and cost-minimizationTimepoint: 1 year
- Secondary Outcome Measures
Name Time Method Correlation of demographic data like socioeconomic status, area, gender and resistance pattern of anti-TB drugsTimepoint: 1 year